{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:57:07Z","timestamp":1778569027978,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.medcli.2013.01.016","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T12:43:42Z","timestamp":1363178622000},"page":"260-264","source":"Crossref","is-referenced-by-count":4,"title":["Tratamiento de la trombocitemia esencial"],"prefix":"10.1016","volume":"141","author":[{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Besses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.01.016_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: Stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.016_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.01.016_bib0020","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2013.01.016_bib0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.016_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medcli.2013.01.016_bib0035","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.medcli.2013.01.016_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.01.016_bib0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complication in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medcli.2013.01.016_bib0055","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2009.013375","article-title":"Blood cell activation in the myeloproliferative neoplasms","volume":"94","author":"Cervantes","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.01.016_bib0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0065","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2013.01.016_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000063063","article-title":"Increased CD11\/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia","volume":"108","author":"Burgaleta","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0075","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0080","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera","volume":"112","author":"Marchetti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0085","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0095","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2013.01.016_bib0105","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0110","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.016_bib0120","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00277-012-1502-6","article-title":"Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia","volume":"91","author":"Mart\u00ednez-Avil\u00e9s","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0125","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medcli.2013.01.016_bib0135","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1182\/blood-2012-02-411215","article-title":"A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera","volume":"119","author":"Hern\u00e1ndez-Boluda","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","article-title":"Management of essential thrombocytemia","volume":"2011","author":"Cervantes","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.medcli.2013.01.016_bib0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.016_bib0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.01.016_bib0160","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"15","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0170","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.01.016_bib0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08467.x","article-title":"Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients","volume":"152","author":"Besses","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.01.016_bib0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: Results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.01.016_bib0185","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.01.016_bib0190","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T21:01:21Z","timestamp":1595538081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313000821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0025775313000821"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.01.016","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}